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ABSTRACT
Background In metastatic clear cell renal cell carcinoma 
(ccRCC), different combination therapies, each including 
anti- PD-1 immune checkpoint blockade (ICB), are applied 
as first- line treatment. Robust predictive biomarkers for 
rational upfront therapy decisions are lacking, although 
they are urgently needed. Recently, we showed that 
CTLA4 promoter methylation predicts response to ICB 
in melanoma. Here, we aimed to investigate CTLA4 
methylation in ccRCC and its utility to serve as a predictive 
biomarker for anti- PD-1 based ICB in metastatic ccRCC.
Methods CTLA4 methylation was analyzed with regard 
to transcriptional gene activity (mRNA expression), 
intratumoral immune cell composition, and clinical course 
in two ccRCC cohorts obtained from The Cancer Genome 
Atlas (TCGA cohort, n=533) and the University Hospital 
Bonn (UHB Non- ICB Cohort, n=116). In addition, CTLA4 
methylation as well as CD8+ T cell infiltrates and PD- L1 
expression were evaluated in pre- treatment samples from 
a multicenter cohort (RCC- ICB Cohort, n=71). Patients 
included in the RCC- ICB Cohort were treated with either 
first line anti- PD-1 based combination therapy (n=25) or 
monotherapy post–tyrosine kinase inhibition in second line 
or later. Analyses were performed with regard to treatment 
response according to RECIST, progression- free survival 
(PFS), event- free survival (EFS), and overall survival (OS) 
following treatment initiation.
Results CTLA4 promoter hypomethylation was 
significantly correlated with CTLA4 mRNA expression, 
lymphocyte infiltration, and poor OS in both primary ccRCC 
cohorts (TCGA: HR 0.30 (95% CI 0.18 to 0.49), p<0.001; 
UHB Non- ICB: HR 0.35 (95% CI 0.16 to 0.75), p=0.007). 
In contrast, CTLA4 promoter hypomethylation predicted 
response and, accordingly, favorable outcomes (PFS and 
OS) in patients with ICB- treated ccRCC, overcompensating 
the negative prognostic value of CTLA4 hypomethylation 
at initial diagnosis. Moreover, in multivariable Cox 
regression, CTLA4 promoter hypomethylation remained an 
independent predictor of improved outcome in ICB- treated 
ccRCC after co- adjustment of the International Metastatic 
Renal Cell Carcinoma Database Consortium score (HR 3.00 
(95% CI 1.47 to 6.28), p=0.003).
Conclusions Our study suggests CTLA4 methylation 
as a powerful predictive biomarker for immunotherapy 
response in metastatic RCC.
BACKGROUND
In the era of cancer immunotherapy, appli-
cation of immune checkpoint blockade 
(ICB) targeting cytotoxic T lymphocyte–
associated protein 4 (CTLA-4) and/or the 
programmed cell death 1 (PD-1/PD- L1) 
axis led to improved clinical outcomes in 
advanced clear cell renal cell carcinoma 
(ccRCC).1–3 Both combination of anti- PD-1 
and anti- CTLA-44 as well as combined anti- 
PD-1/PD- L1 plus a tyrosine kinase inhibitor 
(TKI)5–8 are currently applied as first- line 
therapy in metastatic ccRCC. As prospective 
clinical trials comparing these first- line ther-
apies are still pending, both therapy combi-
nations are currently considered equivalent 
in the intermediate and poor- risk groups 
defined by the International Metastatic 
Renal Cell Carcinoma Database Consortium 
(IMDC). In this context, a robust biomarker 
for an optimal upfront therapy decision and 
treatment sequencing in the clinical setting 
of metastatic ccRCC is missing.1 9
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Tumor- intrinsic PD- L1 expression predicts response 
to anti- PD-1 ICB in various tumor entities, but in ccRCC 
it is of limited use and the European Association of 
Urology recommend not to consider this biomarker 
for patient stratification.10–13 Furthermore, a predictive 
biomarker that evaluates the effectiveness of an anti- 
PD-1 blockade is also of limited relevance in ccRCC, as 
the PD-1/PD- L1 immune axis is targeted in both first- 
line therapies as the current backbone of first- line ccRCC 
therapy. Of note, in CheckMate214, the study that ulti-
mately led to the approval of ICB +ICB in ccRCC, only 
PD- L1 expression was evaluated regarding response 
rates,4 thereby excluding half of the biological mecha-
nism of this therapy approach, precisely the blockade of 
the CTLA-4 immune checkpoint.14 A robust predictive 
biomarker for anti- CTLA-4 monotherapy is also currently 
lacking despite its high clinical relevance, as several 
new antibodies and probodies, which promise reduced 
off- tumor toxicity, are being developed and are already 
tested in clinical trials (eg,  ClinicalTrials. gov Identifier: 
NCT03369223).15 In this context, we were recently able 
to provide strong evidence that the methylation status 
of the CTLA-4 encoding gene CTLA4 predicts response 
to both anti- PD-1 and anti- CTLA-4 targeted ICB as well 
as anti- CTLA-4 monotherapy in patients with mela-
noma.16 17 In the present study, we therefore comprehen-
sively investigated the promoter DNA methylation status 
of CTLA4 in ccRCC with regard to transcriptional activity, 
clinicopathological parameters (including survival and 
response to ICB and TKI), immune cell infiltrates, and 
an interferon-γ signature. Understanding the epigenetic 
regulation of CTLA4 in ccRCC is of major interest, as it 
might be promising as a predictive biomarker to enable 
a more rational therapeutic decision in favor or against 
ICB +ICB in patients with ccRCC in the age of individu-
alized therapy.
METHODS
Patient cohorts and clinical endpoints
TCGA cohort
Comprehensive methylation, expression, and immunog-
enomic data of the ccRCC TCGA dataset generated by 
The Cancer Genome Atlas Research Network (TCGA, http:// 
cancergenome. nih. gov/) were used (n=533).18–20 Event- 
free survival (EFS) was previously recommended as 
a meaningful clinical endpoint for the ccRCC TCGA 
cohort and defined as progression of disease, local or 
distant recurrence, or death due to any cause.21
UHB Non-ICB Cohort
For validation purposes, a second previously described 
ccRCC cohort of patients treated at the University Medical 
Center Bonn (n=116) was included.22 According to the 
TCGA cohort, EFS was considered as a clinically mean-
ingful endpoint in the UHB Non- ICB Cohort.
RCC-ICB Cohort
In addition, a multicenter ICB- treated RCC cohort was 
assembled (see table 1, n=71 also including n=4 non- 
ccRCC). The RCC- ICB Cohort included pre- treatment 
samples from patients who received either anti- PD-1 
monotherapy second- line or later post- TKI (n=46) or 
first- line anti- PD-1 based combination therapy (n=25). 
Clinical endpoints were response to ICB according to 
RECIST V.1.1 and progression- free survival (PFS). PFS 
was defined as the time from ICB initiation until objective 
tumor progression or death. Overall survival (OS) was 
evaluated for all three cohorts.
Transcriptome data assembly
Log2- transformed RSEM (RNA- Seq by Expectation Maxi-
mization) RNA sequencing data (RNA- Seq v2) of CTLA4, 
interferon-γ signature and cytolytic activity genes (IFNG, 
STAT1, STAT2, JAK2, IRF9, GZMA, GZMB, PRF1) gener-
ated by Illumina HiSeq (Illumina, San Diego, CA, USA) 
were downloaded from the UCSC Xena browser (http:// 
xena. ucsc. edu) (ccRCC n=533, normal adjacent tissue 
(NAT) n=72).
Comprehensive immunogenomic data on the compo-
sition of the tumor microenvironment and the interfer-
on-γ signature response of the ccRCC TCGA cohort were 
obtained from Thorsson et al and implemented.20
CTLA4 promoter methylation analysis
The ccRCC TCGA cohort contained comprehensive meth-
ylation data from n=318 ccRCC and n=160 NAT samples. 
The CpG sites cg08460026 (CpG1) and cg05074138 
(CpG2) within the CTLA4 promoter were probed by 
beads from the Infinium HumanMethylation450 Bead-
Chip (Illumina). The genomic organization of CTLA4 is 
illustrated in figure 1A. β values, estimating the ratio of 
intensities between methylated and unmethylated alleles, 
were used for analyses.
In the UHB Non- ICB Cohort (n=116) and the RCC- 
ICB Cohort (n=71), we used a quantitative methylation- 
specific PCR (qMSP) assay in order to determine the 
methylation level of CpG1 within the CTLA4 promoter. 
The qMSP assay contained primers that amplify methyl-
ation—unspecifically a 73 bp amplicon (forward primer: 
attcaattaaatacttaaaattatcttttc, reverse primer: tatatatgt-
gtatatatagaaggtatttg). The assay included two hydrolysis 
probes that specifically and competitively hybridize to 
methylated and unmethylated CTLA4 sequences, respec-
tively (methylated: 6- Fam- cccacgacttcctttctcgtaaa- BHQ-1, 
unmethylated: HEX- acccacaacttcctttctcataaaacc- BHQ-1). 
The assay probes CpG1 and an adjacent CpG site 
(genomic target sequence: CGGCTTCCTTTCTCG). 
We calculated Quantitative Methylation Scores (QMS) 
using the formula: QMS=100/(1+2∧(CTmethylated−CTunmethyl-
ated)).
23 24 We used a PCR buffer composition as described 
earlier25 and ran the PCR for 20 min at 95°C and 40 cycles 
with 15 s at 95°C, 15 s at 55°C, and 60 s at 52°C using a 
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Immunohistochemistry
Immune cell infiltrate scores of CD4+ and CD8+ T cells and 
pan- leukocytes (CD45+) as quantified via immunohistochem-
istry (IHC) on whole slides were included from our previous 
work (UHB Non- ICB Cohort).22 CD8+ T cell infiltration in 
tumors from the multicenter RCC- ICB Cohort was evaluated 
accordingly.22 PD- L1 IHC 22C3 pharmDx (Agilent Technol-
ogies, Santa Clara, CA, USA) was used for the assessment 
of PD- L1 Combined Positive Score (CPS) for the RCC- ICB 
Cohort following the manufacturer’s instructions.
Statistics
Microsoft Excel, GraphPad Prism, and SPSS V.25 were used 
for statistical analyses. Non- parametric Spearman’s ρ correla-
tion coefficients were calculated. Group comparisons were 
made using parametric two- sided Student’s t- test or nonpara-
metric Mann- Whitney U or Kruskal- Wallis (>2 groups) test. 
Survival analyses of median dichotomized variables were 
performed using the log- rank test and visualized via Kaplan- 
Meier plots. Continuous log2- transformed variables were 
used for Cox proportional HR analyses with specified 95% 
CI.
RESULTS
CTLA4 promoter is hypomethylated in ccRCC compared with 
normal adjacent renal tissue (NAT)
We investigated methylation of two CpG sites, referred to as 
CpG1 and CpG2, located in the central promoter region of 
CTLA4 (figure 1A). Interestingly, both evaluated CpG sites 
showed significant hypomethylation in ccRCC compared 
with NAT (p<0.001) and, inversely, CTLA4 mRNA expres-
sion was increased in ccRCC versus NAT (figure 1B–D). In 
addition, both analyzed CpG sites showed a high degree of 
co- methylation (Spearman’s ρ=0.68, p<0.001).
CTLA4 transcriptional activity is associated with its promoter 
methylation
Next, we aimed to analyze to what extent the transcriptional 
activity of the CTLA4 gene is associated with the methylation 
status of its promoter region. In ccRCC, hypomethylation of 
both CpG sites within the promoter was inversely correlated 
with CTLA4 mRNA expression with significant Spearman’s 
correlation coefficients: CpG1 ρ=−0.54; CpG2 ρ=−0.51 (both 
p<0.001, figure 1E,F). Thus, the transcriptional activity of 
the CTLA4 gene strongly depends on its promoter methyla-
tion. In NAT, no significant correlation between the CTLA4 
promoter methylation and its mRNA expression was evident, 
which might be due to a low sample size (n=24) or indicates 
a tumor- specific methylation pattern.
CTLA4 promoter hypomethylation and CTLA4 mRNA 
expression are associated with distinct immune cell 
infiltration and an interferon-γ expression signature
The tumor microenvironment is a complex assembly of 
different immunological cell types. Since tumor immu-
nogenicity is an essential component for the success 
Table 1 Patient characteristics of n=71 patients with metastatic (stage IV) RCC treated with anti- PD-1 ICB and association 





PFS CTLA4 methylation Response
HR (95% CI) P value
Mean QMS 
(SD) P value ORR (n=20)
No ORR 
(n=51)
P value χ² 
test
Median age (range) 65 (44–79) 1.03 (0.99 to 1.06) 0.12     
Sex—no. (%)   0.52 0.58
  Male 49 (69.9) Ref group   73.8 (12.6)   14 (70.0) 35 (68.6)   
  Female 22 (30.1) 0.81 (0.50 to 1.71) 0.81 71.4 (17.6)   6 (30.0) 16 (31.4)   
Sample origin—no. (%)   0.90 0.47
  Primary 58 (81.7) Ref group   73.1 (14.8)   17 (85.0) 41 (80.4)   
  Distant metastasis 13 (13.8) 0.49 (0.22 to 1.13) 0.10 72.6 (12.1)   3 (15.0) 10 (19.9)   
RCC histology—no. (%)   0.010 0.31
  ccRCC 67 (94.4) Ref group   74.1 (12.8)   18 (90.0) 49 (96.1)   
  Non- ccRCC 4 (5.6) 0.63 (0.15 to 2.61) 0.53 55.3 (25.5)   2 (10.0) 2 (3.9)   
ICB response—no. (%)   0.030 ND
  Objective response* 20 (28.2) 0.06 (0.02 to 0.17) <0.001 67.8 (18.5)   20 (100) NA   
  Stable disease 17 (23.9) 0.12 (0.05 to 0.27) <0.001 72.4 (10.7)   NA 17 (33.3)   
  Progressive disease 34 (47.9) Ref group   79.8 (10.8)   NA 34 (66.7)   
P values comparing response refer to χ² test. Methylation levels between two or more groups were compared using Mann- Whitney U and Kruskal- 
Wallis tests, respectively. Cox proportional hazards were tested using Wald test.
*This category included patients with a complete response (n=4) and those with a partial response (n=16). Non- ccRCCs comprised two papillary, one 
chromophobe, and one medullary RCC. The origin of the included tissue of the distant metastases was lung (n=6), bone (n=4), and one each adrenal 
gland, skin, and gallbladder metastasis.
ccRCC, clear cell renal cell carcinoma; ICB, immune checkpoint blockade; NA, not applicable; ND, not determined; ORR, overall response rate; PFS, 
progression- free survival; QMS, Quantitative Methylation Score; RCC, renal cell carcinoma.
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of ICB,14 we next aimed to investigate to what extent 
CTLA4 methylation status is associated with the intra-
tumoral immune cell composition. CTLA4 promoter 
methylation, as well as mRNA expression, significantly 
correlated with the overall lymphocyte infiltration score 
(figure 2A). Considering the different subtypes of the 
lymphoid lineage, it is noteworthy that especially signa-
tures of CD8+ T cells, T follicular helper cells, regulatory 
T cells (Treg), and Th1 cells were associated with upreg-
ulated CTLA4 mRNA expression and concurrent CTLA4 
promoter hypomethylation. In contrast, signatures of 
myeloid infiltration, especially monocytes and macro-
phages (in particular M2 macrophages), was correlated 
with low CTLA4 mRNA expression and accompanying 
promoter hypermethylation. Next, we evaluated the 
relationship between CTLA4 promoter methylation with 
the interferon-γ (IFN-γ) response signature and the cyto-
lytic activity (GZMA, GZMB, PRF1), which are both well 
known to influence ICB efficacy.11 26 Of note, both CTLA4 
promoter hypomethylation and mRNA expression were 
strongly associated with increased IFN- y signatures and 
cytolytic activity (figure 2B).
CTLA4 promoter hypomethylation is associated with an 
unfavorable clinical course in ccRCC
Next, we evaluated to what extent CTLA4 promoter meth-
ylation and CTLA4 transcriptional activity were associated 
with metastatic spread, the crucial step in ccRCC progres-
sion, and clinical outcomes. CTLA4 overexpression and 
concurring hypomethylation in primary ccRCC (TCGA 
cohort) were strongly associated with metastatic spread 
(figure 3A,D). After dichotomization of the cohort by the 
median CTLA4 mRNA expression, the overexpressing 
subgroup exhibited a worse clinical course regarding 
both event- free (EFS, HR 1.23 (95% CI 1.12 to 1.36), 
p<0.001) and overall survival (OS, HR 1.25 (95% CI 1.14 
Figure 1 (A) Genomic organization of the CTLA4 gene and target sites of the Human Methylation450 BeadChip (CpG1: 
cg08460026 and CpG2: cg05074138) and of the quantitative methylation- specific PCR (qMSP). The illustration (modified) was 
taken from Ensembl release 104 and is based on Genome Reference Consortium Human Build 38 patch release 13 (GRCh38.
p13).34 (B–D) CTLA4 mRNA expression and promoter methylation status of CpG1 and CpG2 in normal adjacent tissue (NAT) vs 
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to 1.38), p<0.001, figure 3B,C). In accordance, promoter 
hypomethylation of CpG1 was associated with unfavor-
able EFS (HR 0.36 (95% CI 0.22 to 0.60), p<0.001) and 
OS (HR 0.30 (95% CI 0.18 to 0.49), p<0.001, figure 3E,F). 
The methylation status of CpG2 showed only a trend and 
no significant association with outcome (EFS: HR 0.20 
(95% CI 0.03 to 1.57), p=0.13; OS: HR 0.15 (95% CI 0.02 
to 1.13), p=0.065).
To validate the aforementioned results in an indepen-
dent cohort, we evaluated CTLA4 promoter methylation 
in our UHB Non- ICB Cohort (n=116) using a quantitative 
methylation- specific PCR assay. The qMSP targets CpG1 
and one adjacent CpG site located 13 bp upstream from 
CpG1 (figure 1A). Of note, CTLA4 promoter hypometh-
ylation was correlated with an enriched immune cell 
infiltration pattern (IHC for CD4+, CD8+ T cells and 
pan- leukocytes (CD45+)), which validates the aforemen-
tioned results that were based on immunogenomic RNA- 
Seq signatures (figure 4A). Confirming our results from 
the TCGA cohort, CTLA4 hypomethylation in primary 
ccRCC tissue at initial diagnosis was significantly asso-
ciated with unfavorable EFS (HR 0.36 (95% CI 0.17 to 
0.78), p<0.010) and OS (HR 0.35 (95% CI 0.16 to 0.75), 
p=0.007) in the UHB Non- ICB Cohort (figure 4B,C).
CTLA4 promoter hypomethylation predicts response 
and outcome in metastatic RCC treated with anti-PD-1 
immunotherapy
Since CTLA4 promoter hypomethylation is associated 
with an enhanced immune infiltrate in ccRCC, assess-
ment of CTLA4 methylation status in treatment- naïve 
tissue samples prior to initiation of ICB therapy may have 
predictive value for ICB- treatment success. To evaluate 
the potential predictive value of CTLA4 methylation prior 
to immunotherapy, we have assembled a multicenter 
ICB treated cohort (RCC- ICB Cohort, n=71) of patients 
treated at German tertiary referral centers. As shown in 
primary ccRCC earlier, CTLA4 hypomethylation again 
correlated strongly with CD8+ T cell infiltration in the 
RCC- ICB cohort (Spearman’s ρ=−0.44, p<0.001).
Figure 2 Correlation heatmaps visualize Spearman’s ρ 
correlation coefficients of both the CTLA4 mRNA expression 
and the promoter methylation status (CpG1 +2) with respect 
to the intratumoral immune cell composition (A), the IFN-γ 
response, and cytolytic activity (B), respectively. APC, 
antigen- presenting cell.
Figure 3 Association of the CTLA4 mRNA expression and promoter methylation of CpG1 with respect to the metastatic status 
(M stage, A,D) and the clinical endpoints event- free survival (EFS, B,E) and overall survival (OS, C,F) in the ccRCC TCGA cohort 
are depicted. ccRCC, clear cell renal cell carcinoma.
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Of note, CTLA4 promoter hypomethylation in pre- 
treatment RCC samples predicted ICB- treatment 
response (figure 4D). In concordance with the better 
response of CTLA4 hypomethylated tumors to immuno-
therapy, patients experienced a prolonged PFS and OS 
after ICB treatment initiation (PFS: HR 1.94 (95% CI 1.09 
to 3.44), p=0.024; OS: HR 2.14 (95% CI 1.01 to 4.57), 
p=0.048; figure 4E,F). This finding is of particular impor-
tance because, in contrast, CTLA4 hypomethylation at 
initial diagnosis was associated with worse survival. There-
fore, the positive predictive value of CTLA4 hypometh-
ylation exceeded the negative prognostic value at initial 
diagnosis (TCGA, UHB Non- ICB). For a subgroup of 
n=44 patients in the RCC- ICB Cohort, response data on 
prior or subsequent TKI were available. In contrast to its 
predictive value on immunotherapy, CTLA4 methylation 
status did not predict TKI- treatment success and outcome.
Of note, intratumoral PD- L1 expression (cut- off 
CPS>1) had no predictive value in our multicenter RCC- 
ICB cohort (PFS: HR 1.46 (95% CI 0.78 to 2.74), p=0.24). 
Furthermore, in multivariate Cox regression, CTLA4 
promoter hypomethylation remained an independent 
predictor of improved outcome following ICB- treatment 
initiation after co- adjusting the IMDC risk score (HR 3.00 
(95% CI 1.47 to 6.28), p=0.003).
DISCUSSION
An epigenetic regulation of the CTLA4 gene via DNA 
methylation has already been observed in melanoma.16 
Interestingly, and of particular clinical interest, the CTLA4 
methylation status exhibited a predictive value in patients 
with melanoma treated with anti- PD-1 plus anti- CTLA-4 
immune checkpoint therapy.16 In the current clinical situ-
ation for metastatic ccRCC, a robust predictive biomarker 
for this particular ICB combination therapy, anti- PD-1 plus 
anti- CTLA-4, is urgently needed as the combination of anti- 
PD-1/PD- L1 plus TKI is currently considered equivalent and 
comparative studies are still pending.1 4–6 9 In this study, we 
therefore comprehensively investigated CTLA4 promoter 
methylation with regard to transcriptional activity, clinico-
pathological parameters, and the intratumoral microenvi-
ronment in ccRCC tissue. Of note, we observed a strong 
correlation between the transcriptional activity of CTLA4 
and its promoter methylation status in ccRCC. Moreover, 
CTLA4 promoter methylation and its mRNA expression 
showed a significant association with the composition of the 
ccRCC tumor microenvironment: CTLA4 overexpression 
and concomitant promoter hypomethylation were associ-
ated with particularly high lymphocyte infiltration and an 
increased interferon-γ signature as well as cytolytic activity. 
CTLA4 hypomethylation thus appears to be a robust surro-
gate biomarker for an enriched tumor microenvironment. 
Further, an unfavorable clinical course was evident in 
primary RCC with hypomethylated CTLA4 promoter and 
overexpression, respectively. These findings are in line with 
the literature describing increased immune cell infiltration 
and immune checkpoint expression in RCC as a negative 
prognostic marker.26
Figure 4 (A) CTLA4 promoter hypomethylation is associated with high lymphocyte infiltration, especially CD8+ T cells. (B+C) 
CTLA4 promoter hypomethylation was associated with unfavorable event- free (EFS) and overall survival (OS). (D) In pre- 
treatment RCC samples, CTLA4 promoter hypomethylation predicts immune checkpoint blockade (ICB)–treatment response 
and is associated with prolonged progression- free survival (PFS) after ICB- treatment initiation (E) and favorable OS (F).
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The transcriptomic and methylation data in the ccRCC 
TCGA dataset were obtained from whole tumor tissue 
samples of patients with ccRCC receiving nephrec-
tomy18 19 and are therefore based on the genomic signa-
ture of the tumor and its microenvironment, including 
tumor cells, stroma, infiltrating immune cells, and tumor- 
associated fibroblasts.27 The complexity of epigenetics 
is highlighted by widespread tissue- specific and cell 
type–specific methylation patterns in diverse biological 
processes;28 however, the characterization of an existing 
cell line–specific epigenetic regulation of CTLA4 via DNA 
methylation patterns was not the focus of our study. The 
aim of our study was to investigate a predictive and whole- 
tissue based easy- to- implement biomarker for RCC, and 
excitingly, CTLA4 promoter methylation seems to have 
cancer- independent predictive potential for ICB response 
in melanoma and RCC.16 17
As a chemically stable epigenetic modification that is 
not as dynamic as mRNA or protein expression, DNA 
methylation patterns represent particularly attractive 
biomarkers.29 Furthermore, the fact that quantitative and 
investigator- independent measurement of DNA methyl-
ation is even possible in small samples (microdissected 
cells, liquid biopsies, circulating tumor cells) is a major 
advantage from the diagnostic point of view.30 31 Basing 
the data on CTLA4 DNA methylation shown here and the 
data on CTLA4 methylation in melanoma16 17 strengthen 
the rationale to test this particular methylation biomarker 
in clinical trials. In the present study, we have analyzed 
uncalibrated quantitative methylation levels by means of 
ß values (Illumina Infinium Technology) and QMS values 
(qMSP), respectively. These levels, however, do not neces-
sarily reflect true percentage methylation levels. In order 
to determine percentage methylation, for example, for 
the transfer of clinically relevant cut- offs to different plat-
forms and assay technologies, absolute methodologies, 
that is, bisulfite clone sequencing, could be applied.
The CTLA4 promoter hypomethylated ccRCC subgroup 
was characterized by enhanced immune cell infiltration, 
in particular, CD8+ T cell infiltration indicating these 
tumors as immunologically “hot tumors". Thus, we asked 
the question whether the CTLA4 methylation status in 
treatment- naïve tissue samples prior to initiation of ICB 
therapy has predictive value to immunotherapy in RCC. 
Of note, in our multicenter RCC- ICB cohort, CTLA4 
promoter hypomethylation predicted ICB treatment 
success, which also translated into prolonged PFS and 
OS after ICB treatment initiation, thereby counteracting 
its negative prognostic value in primary ccRCC at initial 
diagnosis. CTLA4 methylation status was not associated 
with TKI response, highlighting that CTLA4 methylation 
appears to be predictive for immunotherapy only. At initial 
diagnosis (TCGA and UHB Non- ICB Cohorts), CTLA4 
promoter hypomethylation was a negative prognostic 
biomarker and associated with poor outcome, whereas in 
metastatic stage prior immunotherapy, it was a favorable 
biomarker. This is most likely due to its predictive value 
since the high response to ICB overcompensated the 
negative prognostic value at initial diagnosis. A similar 
phenomenon has already been described for melanoma. 
PD- L1 upregulation is associated with an aggressive subset 
of melanomas with unfavorable outcome at initial diag-
nosis but has predictive value for ICB response.32 33 Thus, 
negative prognostic biomarkers at baseline with strong 
predictive value for immunotherapy response can over-
come their initial negative prognostic value in advanced 
disease stages. This highlights the potential of CTLA4 
methylation as a promising predictive biomarker prior to 
ICB- treatment initiation in RCC, which has already been 
suggested for melanoma.16 17
In the current clinical setting of metastatic RCC with 
multiple first- line therapies, essentially either ICB+TKI or 
ICB+ICB, there is a tremendous clinical need for robust 
predictive biomarkers for rational upfront therapy selec-
tion, but despite significant efforts, no biomarker that 
can be easily implemented into clinical practice is avail-
able. PD- L1 expression is the only broadly used predictive 
biomarker, but in ccRCC it is of limited clinical use.10–13 
However, patients with ≥1% PD- L1 expression seem to 
benefit particularly from intensified immunotherapy with 
nivolumab plus ipilimumab.3 In our multicenter RCC- 
ICB Cohort, CTLA4 promoter hypomethylation outper-
formed PD- L1 CPS, which had no significant predictive 
value in our cohort. Thus, it remains to be prospectively 
elucidated whether the predictive potential of CTLA4 
promoter methylation status will lead to an improved 
stratification for rational upfront treatment decisions for 
either ICB+TKI or ICB+ICB.
The main limitations of our study are the retrospective 
design, the relative small sample size of our RCC- ICB 
cohort, the heterogeneity of included patients regarding 
histology (clear- cell and non- clear- cell RCC included), 
sample origin (primary tumor and distant metas-
tases), and pre- treatment. In order to establish a robust 
biomarker in this clinical setting, prospective studies are 
needed to determine the clinical performance of CTLA4 
promoter hypomethylation as a predictive biomarker for 
ICB in patients with ccRCC.
CONCLUSION
In ccRCC, the important immune checkpoint CTLA-4 is 
epigenetically regulated by promoter DNA methylation. 
CTLA4 promoter hypomethylation is a strong biomarker 
for poor prognosis in patients with ccRCC at initial diag-
nosis. In contrast, CTLA4 promoter hypomethylation 
predicted response and favorable outcome to immu-
notherapy in our multicenter ICB- treated RCC cohort. 
Thus, it represents a promising candidate for the urgently 
needed predictive biomarker for optimal upfront treat-
ment decision in metastatic ccRCC.
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